Compassionate Use of Stiripentol in Dravet Syndrome

This is a treatment protocol for compassionate use, not a research study, therefore children
will only be monitored on a clinical basis for seizure improvement predominantly by parent
and caregiver report.

Children with genetic confirmation of Dravet syndrome (a documented sodium channel,
voltage-gated, type I, alpha subunit (SCN1A) mutation) or clinical confirmation of Dravet
syndrome by two pediatric neurologist will be considered to have Dravet syndrome. In order
to enter the treatment protocol there will be documented treatment failure of at least two
therapeutic anticonvulsants excluding Na channel blockers. Anticonvulsants that are Na
channel blockers such as carbamazepine and lamotrigine as known to provoke seizures in this
patient population.